nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2C19—Vismodegib—skin cancer	0.122	0.164	CbGbCtD
Methazolamide—CYP2E1—Dacarbazine—skin cancer	0.118	0.159	CbGbCtD
Methazolamide—CYP2C9—Vismodegib—skin cancer	0.102	0.137	CbGbCtD
Methazolamide—CYP3A4—Imiquimod—skin cancer	0.0852	0.115	CbGbCtD
Methazolamide—CYP3A4—Temozolomide—skin cancer	0.0852	0.115	CbGbCtD
Methazolamide—CYP2D6—Vemurafenib—skin cancer	0.0734	0.0987	CbGbCtD
Methazolamide—CYP3A4—Vismodegib—skin cancer	0.0591	0.0794	CbGbCtD
Methazolamide—CYP3A4—Vemurafenib—skin cancer	0.0467	0.0628	CbGbCtD
Methazolamide—CYP2C9—Fluorouracil—skin cancer	0.0361	0.0485	CbGbCtD
Methazolamide—CYP3A4—Docetaxel—skin cancer	0.016	0.0215	CbGbCtD
Methazolamide—CA6—ear—skin cancer	0.0123	0.18	CbGeAlD
Methazolamide—CA6—hair follicle—skin cancer	0.00651	0.0949	CbGeAlD
Methazolamide—Tingling sensation—Imiquimod—skin cancer	0.00446	0.0238	CcSEcCtD
Methazolamide—CA1—nerve—skin cancer	0.00413	0.0602	CbGeAlD
Methazolamide—Photosensitivity—Vemurafenib—skin cancer	0.00348	0.0185	CcSEcCtD
Methazolamide—CA5A—female reproductive system—skin cancer	0.00342	0.0499	CbGeAlD
Methazolamide—CA4—nerve—skin cancer	0.00323	0.0471	CbGeAlD
Methazolamide—Digestion impaired—Temozolomide—skin cancer	0.00322	0.0171	CcSEcCtD
Methazolamide—Dysgeusia—Vismodegib—skin cancer	0.00292	0.0155	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00275	0.0147	CcSEcCtD
Methazolamide—Tingling sensation—Fluorouracil—skin cancer	0.00246	0.0131	CcSEcCtD
Methazolamide—Photosensitivity reaction—Vemurafenib—skin cancer	0.00241	0.0128	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00233	0.0124	CcSEcCtD
Methazolamide—CA2—hair follicle—skin cancer	0.00224	0.0327	CbGeAlD
Methazolamide—Aplastic anaemia—Dactinomycin—skin cancer	0.00223	0.0119	CcSEcCtD
Methazolamide—Dyspepsia—Vismodegib—skin cancer	0.00214	0.0114	CcSEcCtD
Methazolamide—Pancytopenia—Imiquimod—skin cancer	0.00214	0.0114	CcSEcCtD
Methazolamide—Decreased appetite—Vismodegib—skin cancer	0.00211	0.0113	CcSEcCtD
Methazolamide—CA12—connective tissue—skin cancer	0.0021	0.0306	CbGeAlD
Methazolamide—Gastrointestinal disorder—Vismodegib—skin cancer	0.0021	0.0112	CcSEcCtD
Methazolamide—Fatigue—Vismodegib—skin cancer	0.00209	0.0112	CcSEcCtD
Methazolamide—Photosensitivity reaction—Imiquimod—skin cancer	0.00205	0.0109	CcSEcCtD
Methazolamide—Aplastic anaemia—Temozolomide—skin cancer	0.00202	0.0108	CcSEcCtD
Methazolamide—CA9—female reproductive system—skin cancer	0.002	0.0292	CbGeAlD
Methazolamide—Erythema multiforme—Vemurafenib—skin cancer	0.002	0.0106	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.00199	0.0106	CcSEcCtD
Methazolamide—Hepatic failure—Dactinomycin—skin cancer	0.00192	0.0102	CcSEcCtD
Methazolamide—CA6—head—skin cancer	0.00184	0.0269	CbGeAlD
Methazolamide—CA4—nipple—skin cancer	0.00183	0.0267	CbGeAlD
Methazolamide—CA4—neck—skin cancer	0.00181	0.0264	CbGeAlD
Methazolamide—Dysgeusia—Vemurafenib—skin cancer	0.0018	0.00959	CcSEcCtD
Methazolamide—Asthenia—Vismodegib—skin cancer	0.00174	0.00929	CcSEcCtD
Methazolamide—Hepatic failure—Temozolomide—skin cancer	0.00174	0.00925	CcSEcCtD
Methazolamide—Erythema multiforme—Imiquimod—skin cancer	0.0017	0.00908	CcSEcCtD
Methazolamide—Tinnitus—Imiquimod—skin cancer	0.00168	0.00895	CcSEcCtD
Methazolamide—Diarrhoea—Vismodegib—skin cancer	0.00166	0.00886	CcSEcCtD
Methazolamide—Photosensitivity—Fluorouracil—skin cancer	0.00164	0.00873	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00155	0.00828	CcSEcCtD
Methazolamide—CA5B—mammalian vulva—skin cancer	0.00155	0.0226	CbGeAlD
Methazolamide—Vomiting—Vismodegib—skin cancer	0.00154	0.00823	CcSEcCtD
Methazolamide—Rash—Vismodegib—skin cancer	0.00153	0.00816	CcSEcCtD
Methazolamide—Dermatitis—Vismodegib—skin cancer	0.00153	0.00815	CcSEcCtD
Methazolamide—Pancytopenia—Bleomycin—skin cancer	0.00152	0.00809	CcSEcCtD
Methazolamide—CA2—nipple—skin cancer	0.00152	0.0221	CbGeAlD
Methazolamide—CA2—neck—skin cancer	0.0015	0.0219	CbGeAlD
Methazolamide—Anaphylactic shock—Vemurafenib—skin cancer	0.0015	0.008	CcSEcCtD
Methazolamide—CA12—female reproductive system—skin cancer	0.00148	0.0216	CbGeAlD
Methazolamide—Ill-defined disorder—Imiquimod—skin cancer	0.00146	0.00775	CcSEcCtD
Methazolamide—Nausea—Vismodegib—skin cancer	0.00144	0.00769	CcSEcCtD
Methazolamide—Pancytopenia—Dactinomycin—skin cancer	0.00142	0.00755	CcSEcCtD
Methazolamide—Malaise—Imiquimod—skin cancer	0.00141	0.00754	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00141	0.00749	CcSEcCtD
Methazolamide—Haematuria—Bleomycin—skin cancer	0.00136	0.00724	CcSEcCtD
Methazolamide—Convulsion—Imiquimod—skin cancer	0.00136	0.00724	CcSEcCtD
Methazolamide—CA5B—female reproductive system—skin cancer	0.00133	0.0194	CbGeAlD
Methazolamide—Discomfort—Imiquimod—skin cancer	0.00132	0.00703	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00132	0.00702	CcSEcCtD
Methazolamide—Decreased appetite—Vemurafenib—skin cancer	0.0013	0.00695	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.0013	0.0069	CcSEcCtD
Methazolamide—Fatigue—Vemurafenib—skin cancer	0.00129	0.00689	CcSEcCtD
Methazolamide—Pancytopenia—Temozolomide—skin cancer	0.00128	0.00682	CcSEcCtD
Methazolamide—Agranulocytosis—Dactinomycin—skin cancer	0.00124	0.00661	CcSEcCtD
Methazolamide—CA12—head—skin cancer	0.00124	0.018	CbGeAlD
Methazolamide—Photosensitivity reaction—Temozolomide—skin cancer	0.00123	0.00656	CcSEcCtD
Methazolamide—Anorexia—Imiquimod—skin cancer	0.00122	0.0065	CcSEcCtD
Methazolamide—CA1—lymphoid tissue—skin cancer	0.00122	0.0177	CbGeAlD
Methazolamide—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00119	0.00635	CcSEcCtD
Methazolamide—Body temperature increased—Vemurafenib—skin cancer	0.00119	0.00632	CcSEcCtD
Methazolamide—Pancytopenia—Fluorouracil—skin cancer	0.00118	0.00629	CcSEcCtD
Methazolamide—CA1—female reproductive system—skin cancer	0.00117	0.0171	CbGeAlD
Methazolamide—Hepatic failure—Docetaxel—skin cancer	0.00116	0.00615	CcSEcCtD
Methazolamide—Paraesthesia—Imiquimod—skin cancer	0.00115	0.00612	CcSEcCtD
Methazolamide—Somnolence—Imiquimod—skin cancer	0.00114	0.00606	CcSEcCtD
Methazolamide—Photosensitivity reaction—Fluorouracil—skin cancer	0.00113	0.00604	CcSEcCtD
Methazolamide—Erythema multiforme—Dactinomycin—skin cancer	0.00113	0.00601	CcSEcCtD
Methazolamide—Dyspepsia—Imiquimod—skin cancer	0.00113	0.006	CcSEcCtD
Methazolamide—Decreased appetite—Imiquimod—skin cancer	0.00111	0.00593	CcSEcCtD
Methazolamide—CA5B—head—skin cancer	0.00111	0.0162	CbGeAlD
Methazolamide—Gastrointestinal disorder—Imiquimod—skin cancer	0.00111	0.00589	CcSEcCtD
Methazolamide—Fatigue—Imiquimod—skin cancer	0.0011	0.00588	CcSEcCtD
Methazolamide—CA2—connective tissue—skin cancer	0.00108	0.0157	CbGeAlD
Methazolamide—Asthenia—Vemurafenib—skin cancer	0.00108	0.00574	CcSEcCtD
Methazolamide—Feeling abnormal—Imiquimod—skin cancer	0.00106	0.00562	CcSEcCtD
Methazolamide—Agranulocytosis—Fluorouracil—skin cancer	0.00103	0.00551	CcSEcCtD
Methazolamide—Ill-defined disorder—Bleomycin—skin cancer	0.00103	0.00551	CcSEcCtD
Methazolamide—Diarrhoea—Vemurafenib—skin cancer	0.00103	0.00547	CcSEcCtD
Methazolamide—CA2—epithelium—skin cancer	0.00102	0.0149	CbGeAlD
Methazolamide—Erythema multiforme—Temozolomide—skin cancer	0.00102	0.00544	CcSEcCtD
Methazolamide—Urticaria—Imiquimod—skin cancer	0.00102	0.00542	CcSEcCtD
Methazolamide—Body temperature increased—Imiquimod—skin cancer	0.00101	0.00539	CcSEcCtD
Methazolamide—Tinnitus—Temozolomide—skin cancer	0.00101	0.00536	CcSEcCtD
Methazolamide—Malaise—Bleomycin—skin cancer	0.001	0.00535	CcSEcCtD
Methazolamide—Leukopenia—Bleomycin—skin cancer	0.000998	0.00531	CcSEcCtD
Methazolamide—CA1—head—skin cancer	0.000979	0.0143	CbGeAlD
Methazolamide—CA2—skin of body—skin cancer	0.000973	0.0142	CbGeAlD
Methazolamide—Ill-defined disorder—Dactinomycin—skin cancer	0.000964	0.00514	CcSEcCtD
Methazolamide—Vomiting—Vemurafenib—skin cancer	0.000954	0.00508	CcSEcCtD
Methazolamide—Rash—Vemurafenib—skin cancer	0.000947	0.00504	CcSEcCtD
Methazolamide—Dermatitis—Vemurafenib—skin cancer	0.000946	0.00504	CcSEcCtD
Methazolamide—Headache—Vemurafenib—skin cancer	0.00094	0.00501	CcSEcCtD
Methazolamide—Discomfort—Bleomycin—skin cancer	0.000937	0.00499	CcSEcCtD
Methazolamide—Malaise—Dactinomycin—skin cancer	0.000937	0.00499	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000935	0.00498	CcSEcCtD
Methazolamide—Leukopenia—Dactinomycin—skin cancer	0.00093	0.00496	CcSEcCtD
Methazolamide—Dysgeusia—Temozolomide—skin cancer	0.000921	0.0049	CcSEcCtD
Methazolamide—Asthenia—Imiquimod—skin cancer	0.000919	0.00489	CcSEcCtD
Methazolamide—Confusional state—Bleomycin—skin cancer	0.000917	0.00489	CcSEcCtD
Methazolamide—CA4—female reproductive system—skin cancer	0.000916	0.0134	CbGeAlD
Methazolamide—Anaphylactic shock—Bleomycin—skin cancer	0.00091	0.00484	CcSEcCtD
Methazolamide—Nausea—Vemurafenib—skin cancer	0.000892	0.00475	CcSEcCtD
Methazolamide—CA2—mammalian vulva—skin cancer	0.000887	0.0129	CbGeAlD
Methazolamide—Diarrhoea—Imiquimod—skin cancer	0.000876	0.00467	CcSEcCtD
Methazolamide—Discomfort—Dactinomycin—skin cancer	0.000874	0.00466	CcSEcCtD
Methazolamide—Ill-defined disorder—Temozolomide—skin cancer	0.000872	0.00465	CcSEcCtD
Methazolamide—Anorexia—Bleomycin—skin cancer	0.000867	0.00462	CcSEcCtD
Methazolamide—Pancytopenia—Docetaxel—skin cancer	0.000852	0.00454	CcSEcCtD
Methazolamide—Malaise—Temozolomide—skin cancer	0.000848	0.00452	CcSEcCtD
Methazolamide—Vertigo—Temozolomide—skin cancer	0.000845	0.0045	CcSEcCtD
Methazolamide—Leukopenia—Temozolomide—skin cancer	0.000841	0.00448	CcSEcCtD
Methazolamide—Paraesthesia—Bleomycin—skin cancer	0.000817	0.00435	CcSEcCtD
Methazolamide—Convulsion—Temozolomide—skin cancer	0.000814	0.00434	CcSEcCtD
Methazolamide—Vomiting—Imiquimod—skin cancer	0.000814	0.00434	CcSEcCtD
Methazolamide—Anorexia—Dactinomycin—skin cancer	0.000809	0.00431	CcSEcCtD
Methazolamide—Rash—Imiquimod—skin cancer	0.000807	0.0043	CcSEcCtD
Methazolamide—Dermatitis—Imiquimod—skin cancer	0.000806	0.0043	CcSEcCtD
Methazolamide—Headache—Imiquimod—skin cancer	0.000802	0.00427	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000793	0.00422	CcSEcCtD
Methazolamide—Discomfort—Temozolomide—skin cancer	0.000791	0.00421	CcSEcCtD
Methazolamide—Decreased appetite—Bleomycin—skin cancer	0.000791	0.00421	CcSEcCtD
Methazolamide—CA2—lymphoid tissue—skin cancer	0.000788	0.0115	CbGeAlD
Methazolamide—CA5B—lymph node—skin cancer	0.000776	0.0113	CbGeAlD
Methazolamide—Leukopenia—Fluorouracil—skin cancer	0.000775	0.00413	CcSEcCtD
Methazolamide—Confusional state—Temozolomide—skin cancer	0.000774	0.00412	CcSEcCtD
Methazolamide—Anaphylactic shock—Temozolomide—skin cancer	0.000767	0.00409	CcSEcCtD
Methazolamide—CA4—head—skin cancer	0.000765	0.0112	CbGeAlD
Methazolamide—Nausea—Imiquimod—skin cancer	0.00076	0.00405	CcSEcCtD
Methazolamide—CA2—female reproductive system—skin cancer	0.00076	0.0111	CbGeAlD
Methazolamide—Convulsion—Fluorouracil—skin cancer	0.00075	0.004	CcSEcCtD
Methazolamide—Feeling abnormal—Bleomycin—skin cancer	0.000749	0.00399	CcSEcCtD
Methazolamide—Agranulocytosis—Docetaxel—skin cancer	0.000747	0.00398	CcSEcCtD
Methazolamide—Decreased appetite—Dactinomycin—skin cancer	0.000737	0.00393	CcSEcCtD
Methazolamide—Fatigue—Dactinomycin—skin cancer	0.000731	0.0039	CcSEcCtD
Methazolamide—Anorexia—Temozolomide—skin cancer	0.000731	0.0039	CcSEcCtD
Methazolamide—Discomfort—Fluorouracil—skin cancer	0.000729	0.00388	CcSEcCtD
Methazolamide—Urticaria—Bleomycin—skin cancer	0.000723	0.00385	CcSEcCtD
Methazolamide—Body temperature increased—Bleomycin—skin cancer	0.000719	0.00383	CcSEcCtD
Methazolamide—Confusional state—Fluorouracil—skin cancer	0.000713	0.0038	CcSEcCtD
Methazolamide—Anaphylactic shock—Fluorouracil—skin cancer	0.000707	0.00377	CcSEcCtD
Methazolamide—Feeling abnormal—Dactinomycin—skin cancer	0.000699	0.00372	CcSEcCtD
Methazolamide—Paraesthesia—Temozolomide—skin cancer	0.000689	0.00367	CcSEcCtD
Methazolamide—CA1—lymph node—skin cancer	0.000686	0.01	CbGeAlD
Methazolamide—Somnolence—Temozolomide—skin cancer	0.000682	0.00363	CcSEcCtD
Methazolamide—Erythema multiforme—Docetaxel—skin cancer	0.000679	0.00362	CcSEcCtD
Methazolamide—Dyspepsia—Temozolomide—skin cancer	0.000675	0.0036	CcSEcCtD
Methazolamide—Anorexia—Fluorouracil—skin cancer	0.000674	0.00359	CcSEcCtD
Methazolamide—Body temperature increased—Dactinomycin—skin cancer	0.000671	0.00357	CcSEcCtD
Methazolamide—Decreased appetite—Temozolomide—skin cancer	0.000667	0.00355	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000662	0.00353	CcSEcCtD
Methazolamide—Fatigue—Temozolomide—skin cancer	0.000661	0.00352	CcSEcCtD
Methazolamide—Asthenia—Bleomycin—skin cancer	0.000653	0.00348	CcSEcCtD
Methazolamide—CYP2C9—female reproductive system—skin cancer	0.000643	0.00937	CbGeAlD
Methazolamide—Paraesthesia—Fluorouracil—skin cancer	0.000635	0.00338	CcSEcCtD
Methazolamide—CA2—head—skin cancer	0.000635	0.00926	CbGeAlD
Methazolamide—Feeling abnormal—Temozolomide—skin cancer	0.000632	0.00337	CcSEcCtD
Methazolamide—CYP2E1—lymphoid tissue—skin cancer	0.000632	0.00921	CbGeAlD
Methazolamide—Somnolence—Fluorouracil—skin cancer	0.000628	0.00335	CcSEcCtD
Methazolamide—Dyspepsia—Fluorouracil—skin cancer	0.000622	0.00331	CcSEcCtD
Methazolamide—Decreased appetite—Fluorouracil—skin cancer	0.000615	0.00327	CcSEcCtD
Methazolamide—Dysgeusia—Docetaxel—skin cancer	0.000612	0.00326	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00061	0.00325	CcSEcCtD
Methazolamide—Urticaria—Temozolomide—skin cancer	0.000609	0.00325	CcSEcCtD
Methazolamide—CYP2E1—female reproductive system—skin cancer	0.000609	0.00888	CbGeAlD
Methazolamide—Asthenia—Dactinomycin—skin cancer	0.000609	0.00324	CcSEcCtD
Methazolamide—Body temperature increased—Temozolomide—skin cancer	0.000606	0.00323	CcSEcCtD
Methazolamide—Feeling abnormal—Fluorouracil—skin cancer	0.000583	0.0031	CcSEcCtD
Methazolamide—Diarrhoea—Dactinomycin—skin cancer	0.00058	0.00309	CcSEcCtD
Methazolamide—Vomiting—Bleomycin—skin cancer	0.000578	0.00308	CcSEcCtD
Methazolamide—Rash—Bleomycin—skin cancer	0.000573	0.00305	CcSEcCtD
Methazolamide—Dermatitis—Bleomycin—skin cancer	0.000573	0.00305	CcSEcCtD
Methazolamide—Urticaria—Fluorouracil—skin cancer	0.000562	0.00299	CcSEcCtD
Methazolamide—Leukopenia—Docetaxel—skin cancer	0.00056	0.00298	CcSEcCtD
Methazolamide—Body temperature increased—Fluorouracil—skin cancer	0.000559	0.00298	CcSEcCtD
Methazolamide—Asthenia—Temozolomide—skin cancer	0.00055	0.00293	CcSEcCtD
Methazolamide—Convulsion—Docetaxel—skin cancer	0.000542	0.00289	CcSEcCtD
Methazolamide—Nausea—Bleomycin—skin cancer	0.00054	0.00288	CcSEcCtD
Methazolamide—Vomiting—Dactinomycin—skin cancer	0.000539	0.00287	CcSEcCtD
Methazolamide—CA4—lymph node—skin cancer	0.000536	0.00782	CbGeAlD
Methazolamide—Rash—Dactinomycin—skin cancer	0.000535	0.00285	CcSEcCtD
Methazolamide—Diarrhoea—Temozolomide—skin cancer	0.000525	0.0028	CcSEcCtD
Methazolamide—Confusional state—Docetaxel—skin cancer	0.000514	0.00274	CcSEcCtD
Methazolamide—Anaphylactic shock—Docetaxel—skin cancer	0.00051	0.00272	CcSEcCtD
Methazolamide—CYP2E1—head—skin cancer	0.000509	0.00742	CbGeAlD
Methazolamide—Nausea—Dactinomycin—skin cancer	0.000504	0.00268	CcSEcCtD
Methazolamide—CYP3A4—female reproductive system—skin cancer	0.00049	0.00715	CbGeAlD
Methazolamide—Vomiting—Temozolomide—skin cancer	0.000488	0.0026	CcSEcCtD
Methazolamide—Anorexia—Docetaxel—skin cancer	0.000486	0.00259	CcSEcCtD
Methazolamide—Rash—Temozolomide—skin cancer	0.000484	0.00258	CcSEcCtD
Methazolamide—Diarrhoea—Fluorouracil—skin cancer	0.000484	0.00258	CcSEcCtD
Methazolamide—Dermatitis—Temozolomide—skin cancer	0.000483	0.00257	CcSEcCtD
Methazolamide—CYP2D6—female reproductive system—skin cancer	0.000482	0.00703	CbGeAlD
Methazolamide—Headache—Temozolomide—skin cancer	0.000481	0.00256	CcSEcCtD
Methazolamide—Paraesthesia—Docetaxel—skin cancer	0.000458	0.00244	CcSEcCtD
Methazolamide—Nausea—Temozolomide—skin cancer	0.000456	0.00243	CcSEcCtD
Methazolamide—Somnolence—Docetaxel—skin cancer	0.000454	0.00242	CcSEcCtD
Methazolamide—Vomiting—Fluorouracil—skin cancer	0.000449	0.00239	CcSEcCtD
Methazolamide—Dyspepsia—Docetaxel—skin cancer	0.000449	0.00239	CcSEcCtD
Methazolamide—Rash—Fluorouracil—skin cancer	0.000446	0.00237	CcSEcCtD
Methazolamide—Dermatitis—Fluorouracil—skin cancer	0.000445	0.00237	CcSEcCtD
Methazolamide—CA2—lymph node—skin cancer	0.000444	0.00648	CbGeAlD
Methazolamide—Decreased appetite—Docetaxel—skin cancer	0.000444	0.00236	CcSEcCtD
Methazolamide—Headache—Fluorouracil—skin cancer	0.000443	0.00236	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Docetaxel—skin cancer	0.00044	0.00235	CcSEcCtD
Methazolamide—Fatigue—Docetaxel—skin cancer	0.00044	0.00234	CcSEcCtD
Methazolamide—Feeling abnormal—Docetaxel—skin cancer	0.00042	0.00224	CcSEcCtD
Methazolamide—Nausea—Fluorouracil—skin cancer	0.00042	0.00224	CcSEcCtD
Methazolamide—Body temperature increased—Docetaxel—skin cancer	0.000403	0.00215	CcSEcCtD
Methazolamide—CYP2D6—head—skin cancer	0.000403	0.00588	CbGeAlD
Methazolamide—Asthenia—Docetaxel—skin cancer	0.000366	0.00195	CcSEcCtD
Methazolamide—Diarrhoea—Docetaxel—skin cancer	0.000349	0.00186	CcSEcCtD
Methazolamide—Vomiting—Docetaxel—skin cancer	0.000324	0.00173	CcSEcCtD
Methazolamide—Rash—Docetaxel—skin cancer	0.000322	0.00171	CcSEcCtD
Methazolamide—Dermatitis—Docetaxel—skin cancer	0.000321	0.00171	CcSEcCtD
Methazolamide—Headache—Docetaxel—skin cancer	0.00032	0.0017	CcSEcCtD
Methazolamide—Nausea—Docetaxel—skin cancer	0.000303	0.00161	CcSEcCtD
